A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

February 24, 2025

Study Completion Date

March 5, 2025

Conditions

Diabetes Mellitus, Type 2ObesityOverweight

Interventions

DRUG

NNC0487-0111

Participants will administer a single dose of NNC0487-0111 subcutaneously using NovoPen®4 by injection into a skinfold on the abdomen.

Trial Locations (1)

Charité Research Organisation GmbH, Berlin